[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK1007520T3 - 2-aminopyridiner som indeholder sammensluttede ringsubstituenter som NOS inhibitorer - Google Patents

2-aminopyridiner som indeholder sammensluttede ringsubstituenter som NOS inhibitorer

Info

Publication number
DK1007520T3
DK1007520T3 DK98935249T DK98935249T DK1007520T3 DK 1007520 T3 DK1007520 T3 DK 1007520T3 DK 98935249 T DK98935249 T DK 98935249T DK 98935249 T DK98935249 T DK 98935249T DK 1007520 T3 DK1007520 T3 DK 1007520T3
Authority
DK
Denmark
Prior art keywords
ring substituents
nos inhibitors
linked ring
containing linked
aminopyridines containing
Prior art date
Application number
DK98935249T
Other languages
Danish (da)
English (en)
Inventor
John Adams Lowe Iii
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK1007520T3 publication Critical patent/DK1007520T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK98935249T 1997-08-27 1998-08-11 2-aminopyridiner som indeholder sammensluttede ringsubstituenter som NOS inhibitorer DK1007520T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5709497P 1997-08-27 1997-08-27
PCT/IB1998/001229 WO1999010339A1 (en) 1997-08-27 1998-08-11 2-aminopyridines containing fused ring substituents as nos inhibitors

Publications (1)

Publication Number Publication Date
DK1007520T3 true DK1007520T3 (da) 2003-11-24

Family

ID=22008463

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98935249T DK1007520T3 (da) 1997-08-27 1998-08-11 2-aminopyridiner som indeholder sammensluttede ringsubstituenter som NOS inhibitorer

Country Status (40)

Country Link
EP (1) EP1007520B1 (sh)
JP (1) JP3411271B2 (sh)
KR (1) KR100367277B1 (sh)
CN (1) CN1268133A (sh)
AP (1) AP1213A (sh)
AR (1) AR014110A1 (sh)
AT (1) ATE248161T1 (sh)
AU (1) AU8458898A (sh)
BG (1) BG104138A (sh)
BR (1) BR9811555A (sh)
CA (1) CA2296313C (sh)
CO (1) CO4970728A1 (sh)
DE (1) DE69817584T2 (sh)
DK (1) DK1007520T3 (sh)
DZ (1) DZ2594A1 (sh)
EA (1) EA003839B1 (sh)
ES (1) ES2203976T3 (sh)
GT (1) GT199800128A (sh)
HN (1) HN1998000118A (sh)
HR (1) HRP980470A2 (sh)
HU (1) HUP0003700A3 (sh)
ID (1) ID24087A (sh)
IL (1) IL133958A0 (sh)
IS (1) IS5344A (sh)
MA (1) MA26537A1 (sh)
NO (1) NO20000958L (sh)
NZ (1) NZ502281A (sh)
OA (1) OA11288A (sh)
PA (1) PA8456901A1 (sh)
PE (1) PE106599A1 (sh)
PL (1) PL338987A1 (sh)
PT (1) PT1007520E (sh)
SK (1) SK1402000A3 (sh)
TN (1) TNSN98154A1 (sh)
TR (1) TR200000535T2 (sh)
UA (1) UA55461C2 (sh)
UY (1) UY25158A1 (sh)
WO (1) WO1999010339A1 (sh)
YU (1) YU10900A (sh)
ZA (1) ZA987726B (sh)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010049379A1 (en) 1997-08-27 2001-12-06 Lowe John Adams 2-aminopyridines containing fused ring substituents
DE69919149D1 (de) 1998-04-10 2004-09-09 Japan Tobacco Inc Amidin-verbindungen
OA11557A (en) * 1998-06-03 2004-05-24 Pfizer Prod Inc 2-Aminopyridines containing fused ring substituents as nitric oxide synthase inhibitors.
KR20010085364A (ko) * 1998-08-11 2001-09-07 데이비드 존 우드 Ｎｏｓ 억제제에 대한 신규 제약 용도
OA11841A (en) 1999-02-25 2005-08-22 Pfizer Prod Inc 2-Aminopyridines containing fused ring substituents.
GB0004152D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
GB0004149D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
GB0004151D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
GB0004153D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
FR2805818B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
CZ200380A3 (cs) 2000-08-16 2004-01-14 Pharmacia & Upjohn Company Sloučeniny pro léčbu poruch spojených se závislostmi
PL208074B1 (pl) 2001-05-15 2011-03-31 Hoffmann La Roche Pochodne oksazolu, sposób ich wytwarzania, środek farmaceutyczny i zastosowanie pochodnych oksazolu
SE0102640D0 (sv) 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
DE10159922A1 (de) * 2001-12-06 2003-06-26 Gruenenthal Gmbh Substituierte 2-Pyrrolidin-2-yl-1H-indol-Derivate
CN100402510C (zh) 2002-07-03 2008-07-16 霍夫曼-拉罗奇有限公司 噁唑衍生物及其作为胰岛素敏化剂的应用
DE60318860T2 (de) * 2002-08-14 2008-05-21 Neurosearch A/S Chinucledin - derivate und deren verwendung
NZ537897A (en) 2002-08-30 2007-08-31 Hoffmann La Roche Novel 2-arylthiazole compounds as PPARalpha and PPARgamma agonists
SI1539746T1 (sl) 2002-09-12 2007-04-30 Hoffmann La Roche Spojine n-substituirane-1h-indol-5-propionske kisline kot agonisti ppar, ki so uporabne za zdravljenje diabetesa
US20040092741A1 (en) * 2002-11-08 2004-05-13 Pfizer Inc Substituted pyridines via boronic acid coupling
AU2003292030B2 (en) 2002-11-25 2007-01-04 F. Hoffmann-La Roche Ag Indolyl derivatives
WO2006065233A1 (en) * 2004-12-10 2006-06-22 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US7655657B2 (en) 2003-12-22 2010-02-02 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US7160876B2 (en) * 2003-12-22 2007-01-09 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
JP2008505926A (ja) * 2004-07-09 2008-02-28 グラクソ　グループ　リミテッド 抗細菌剤
WO2009029592A1 (en) * 2007-08-27 2009-03-05 Kalypsys, Inc. Heterobicyclic-substituted quinolones useful as nitric oxide synthase inhibitors
WO2009029617A1 (en) * 2007-08-27 2009-03-05 Kalypsys, Inc. Diarylamine-substituted quinolones useful as inducible nitric oxide synthase inhibitors
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
DE102008054141A1 (de) 2008-10-31 2010-05-06 Merck Patent Gmbh Neue Materialien für organische Elektrolumineszenzvorrichtungen
DE102009033371A1 (de) 2009-07-16 2011-05-12 Merck Patent Gmbh Materialien für elektronische Vorrichtungen
US9120750B2 (en) 2013-03-07 2015-09-01 Northwestern University 2-Aminopyridine-based selective neuronal nitric oxide synthase inhibitors
CN104725249B (zh) * 2013-12-20 2019-02-12 广东东阳光药业有限公司 苄胺类衍生物及其在药物上的应用
US10759791B2 (en) 2014-11-04 2020-09-01 Northwestern University Mammalian and bacterial nitric oxide synthase inhibitors
US9951014B2 (en) 2014-11-04 2018-04-24 Northwestern University Mammalian and bacterial nitric oxide synthase inhibitors
CN106478376A (zh) * 2016-10-08 2017-03-08 贵州大学 一种4‑氟萘‑1‑醇的制备工艺
CN113365615A (zh) * 2018-12-17 2021-09-07 戈达瓦里生物炼制有限责任公司 抑制不受调控细胞生长的化合物
CN114560779B (zh) * 2022-01-25 2024-06-25 杭州华东医药集团浙江华义制药有限公司 一种米拉贝隆关键中间体的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT400845B (de) * 1993-12-06 1996-03-25 Chem Pharm Forsch Gmbh Neue thienothiazinderivate, ein verfahren zu ihrer herstellung und ihre verwendung
AU4515696A (en) * 1994-12-12 1996-07-03 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
JPH08311028A (ja) * 1995-05-17 1996-11-26 Japan Tobacco Inc ２−アミノピリジン誘導体及びそれら化合物を含有してなる一酸化窒素合成酵素阻害剤
JPH09132529A (ja) * 1995-11-09 1997-05-20 Ono Pharmaceut Co Ltd 一酸化窒素合成酵素阻害剤
WO1997036871A1 (en) * 1996-03-29 1997-10-09 Pfizer Inc. 6-phenylpyridyl-2-amine derivatives
HN1997000027A (es) * 1996-12-06 1997-06-05 Pfizer Prod Inc Derivados de 6-fenil piridil - 2 amina

Also Published As

Publication number Publication date
PA8456901A1 (es) 2000-05-24
WO1999010339A1 (en) 1999-03-04
CA2296313A1 (en) 1999-03-04
ID24087A (id) 2000-07-06
DE69817584T2 (de) 2004-04-01
IS5344A (is) 2000-01-14
NZ502281A (en) 2002-09-27
KR20010022433A (ko) 2001-03-15
ES2203976T3 (es) 2004-04-16
BR9811555A (pt) 2000-09-12
AP1213A (en) 2003-10-07
JP2001514176A (ja) 2001-09-11
HUP0003700A2 (hu) 2001-10-28
DZ2594A1 (fr) 2003-02-22
PL338987A1 (en) 2000-12-04
EA003839B1 (ru) 2003-10-30
TNSN98154A1 (fr) 2005-03-15
ZA987726B (en) 2000-02-28
PE106599A1 (es) 1999-11-02
CO4970728A1 (es) 2000-11-07
OA11288A (en) 2003-08-22
EP1007520A1 (en) 2000-06-14
HN1998000118A (es) 1999-02-09
UA55461C2 (uk) 2003-04-15
AR014110A1 (es) 2001-02-07
BG104138A (en) 2000-11-30
SK1402000A3 (en) 2000-07-11
EP1007520B1 (en) 2003-08-27
NO20000958L (no) 2000-04-14
GT199800128A (es) 2000-02-01
TR200000535T2 (tr) 2000-11-21
UY25158A1 (es) 2000-12-29
EA200000171A1 (ru) 2000-10-30
KR100367277B1 (ko) 2003-01-09
CA2296313C (en) 2004-11-02
CN1268133A (zh) 2000-09-27
DE69817584D1 (de) 2003-10-02
IL133958A0 (en) 2001-04-30
YU10900A (sh) 2002-12-10
HUP0003700A3 (en) 2002-09-30
NO20000958D0 (no) 2000-02-25
PT1007520E (pt) 2003-12-31
MA26537A1 (fr) 2004-12-20
JP3411271B2 (ja) 2003-05-26
HRP980470A2 (en) 1999-06-30
AP9801330A0 (en) 1998-09-30
ATE248161T1 (de) 2003-09-15
AU8458898A (en) 1999-03-16

Similar Documents

Publication Publication Date Title
DK1007520T3 (da) 2-aminopyridiner som indeholder sammensluttede ringsubstituenter som NOS inhibitorer
NO992725L (no) 6-Fenylpyridyl-2-amin-derivater anvendelige som NOS-inhibitorer
DK0818448T3 (da) Cycloalkanopyridiner som CETP-inhibitorer
DK2253620T3 (da) Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
DK1049695T3 (da) 2-Phenyl-substituerede imidazotriazinoner som phosphodiesterase-inhibitorer
DK1001934T3 (da) Indolforbindelser som COX-2-inhibitorer
EE9900259A (et) Ühendi uus vorm
DK0912518T3 (da) Substituerede pyridiner som selektive cyclooxygenase-2 inhibitorer
NO992821D0 (no) Ketobenzamider som calpain-inhibitorer
NO986090D0 (no) Fenylalaninderivater som integrininhibitorer
DK1930330T3 (da) Pleuromutilinderivater som antimikrobielle midler
DK0975623T3 (da) Indazolamidforbindelser som sertoninerge midler
DK1226143T3 (da) Imidazopyridinderivater som phosphodiesterase VII-inhibitorer
DK1007512T3 (da) Forgrenede alkoxysubstituerede 2-aminopyridiner som NOS-inhibitorer
NO20001924D0 (no) Isoquinoliner som urokinase-inhibitorer
NO20016201D0 (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
NO20021251D0 (no) Tienoisoksazolyl- og tienylpyrrazolyl-fenoksysubstituerte propylderivater anvendelige som D4antagonister
DK1155000T3 (da) 2-aminopyridiner som indeholder sammensluttede ringsubstituenser
NO994106D0 (no) Oksazolidiner som 5-HT2A-antagonister
DK1075471T3 (da) Idolylderivater som serotonerge midler
AP9901558A0 (en) 2-Aminopyridines containing used ring substituents
NO20002321D0 (no) Bifenylderivater som farmasøytiske midler
DK1073651T3 (da) Indolylderivater som serotonerge midler
NO20000094L (no) 6-Azaurcilderivater som IL-5 inhibitorer
DK0944601T3 (da) Heterocykliske quanidinylaminoforbindelser som alfa-2-adrenoceptoragonister